Anti-inflammatory effect of fluvastatin on IL-8 production induced by pseudomonas aeruginosa and aspergillus fumigatus antigens in cystic fibrosis

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Jouneau, Stéphane ^a,b   Bonizec, Mélanie ^a   Belleguic, Chantal ^b   Desrues, Benoit ^b   Brinchault, Graziella ^b   Galaine, Jeanne ^a   Gangneux, Jean Pierre ^a,b   Martin Chouly, Corinne ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BACTERIAL ANTIGEN; CHOLESTEROL; CORTICOSTEROID; DEOXYRIBONUCLEASE; FARNESYL DIPHOSPHATE; FLUINDOSTATIN; FUNGUS ANTIGEN; GERANYLGERANYL PYROPHOSPHATE; GUANOSINE TRIPHOSPHATASE; INTERLEUKIN 8; MEVALONIC ACID; PYRROLE; ANTIINFLAMMATORY AGENT; INDOLE DERIVATIVE; LIPOPOLYSACCHARIDE; MONOUNSATURATED FATTY ACID; TERPENE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; BLOOD SAMPLING; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRANCE; HUMAN; ISOPRENYLATION; MALE; PROTEIN BLOOD LEVEL; PSEUDOMONAS AERUGINOSA; ADOLESCENT; CASE CONTROL STUDY; GENETICS; IC 50; METABOLISM; MICROBIOLOGY; MUTATION; PHYSIOLOGY;

ASPERGILLUS FUMIGATUS; BACTERIA (MICROORGANISMS); FUNGI; PSEUDOMONAS AERUGINOSA;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIGENS, FUNGAL; ASPERGILLUS FUMIGATUS; CASE-CONTROL STUDIES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; MALE; MEVALONIC ACID; MUTATION; PSEUDOMONAS AERUGINOSA; TERPENES; YOUNG ADULT;

EID: 79961090074     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022655     Document Type: Article

References (53)

1. van Heeckeren AM, Tscheikuna J, Walenga RW, Konstan MW, Davis PB, et al. (2000) Effect of Pseudomonas infection on weight loss, lung mechanics, and cytokines in mice. Am J Respir Crit Care Med 161: 271-279.
2. Vandivier RW, Richens TR, Horstmann SA, deCathelineau AM, Ghosh M, et al. (2009) Dysfunctional cystic fibrosis transmembrane conductance regulator inhibits phagocytosis of apoptotic cells with proinflammatory consequences. Am J Physiol Lung Cell Mol Physiol 297: L677-L686.
3. Konstan MW, Schluchter MD, Xue W, Davis PB, (2007) Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 176: 1084-1089.
4. Lands LC, Milner R, Cantin AM, Manson D, Corey M, (2007) High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 151: 249-254.
5. Vaughan CJ, Murphy MB, Buckley BM, (1996) Statins do more than just lower cholesterol. Lancet 348: 1079-1082.
6. Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, et al. (2003) A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170: 1524-1530.
7. McKay A, Leung BP, McInnes IB, Thomson NC, Liew FY, (2004) A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 172: 2903-2908.
8. Lindhom MW, Nilsson J, (2007) Simvastatin stimulates interleukine-1β secretion through an isoprenylation-dependent mechanism. Vasc Pharmacol 46: 91-96.
9. Ehrenstein MR, Jury EC, Mauri C, (2005) Statins for atherosclerosis - as good as it gets? N Engl J Med 352: 73-75.
10. Ferro D, Parrotto S, Basili S, Alessandri C, Violi F, (2000) Simvastatin inhibits the monocyte expression of pro-inflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 36: 427-431.
11. Björkhem-Bergman L, Bergman P, Andersson J, Lindh JD, (2010) Statin treatment and mortality in bacterial infections-a systematic review and meta-analysis. PLoS One 5: e10702.
12. Keddissi JI, Younis WG, Chbeir EA, Daher NN, Dernaika TA, et al. (2007) The use of statins and lung function in current and former smokers. Chest 132: 1764-1771.
13. Lee JH, Lee DS, Kim EK, Choe KH, Oh YM, et al. (2005) Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 172: 987-993.
14. Zeki AA, Franzi L, Last J, Kenyon NJ, (2009) Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med 180: 731-740.
15. Jacobson JR, Barnard JW, Grigoryev DN, Ma SF, Tuder RM, et al. (2005) Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 288: L1026-L1032.
16. Yao HW, Mao LG, Zhu JP, (2006) Protective effects of pravastatin in murine lipopolysaccharide-induced acute lung injury. Clin Exp Pharmacol Physiol 33: 793-797.
17. Hartung T, Doecke WD, Bundschuh D, Foote MA, Gantner F, et al. (1999) Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions. Clin Pharmacol Ther 66: 415-424.
18. Bjerre A, Brusletto B, Høiby EA, Kierulf P, Brandtzaeg P, (2004) Plasma interferon-gamma and interleukin-10 concentrations in systemic meningococcal disease compared with severe systemic Gram-positive septic shock. Crit Care Med 32: 433-438.
19. Ouagued M, Martin-Chouly CA, Brinchault G, Leportier-Comoy C, Depincé A, et al. (2005) The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients. Pulm Pharmacol Ther 18: 49-54.
20. Gilligan PH, (1991) Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 4: 35-51.
21. Cazalis J, Bodet C, Gagnon G, Grenier D, (2008) Doxycycline reduces lipopolysaccharide-induced inflammatory mediator secretion in macrophage and ex vivo human whole blood models. J Periodontol 79: 1762-1768.
22. Bellanger AP, Millon L, Khoufache K, Rivollet D, Bièche I, et al. (2009) Aspergillus fumigatus germ tube growth and not conidia ingestion induces expression of inflammatory mediator genes in the human lung epithelial cell line A549. J Med Microbiol 58: 174-179.
23. Svanborg C, Godaly G, Hedlund M, (1999) Cytokine responses during mucosal infections: role in disease pathogenesis and host defence. Curr Opin Microbiol 2: 99-105.
24. Kuwahara I, Lillehoj EP, Lu WJ, Singh IS, Isohama Y, et al. (2006) Neutrophil elastase induces IL-8 gene transcription and protein release through p38/NF-κB activation via EGFR transactivation in a lung epithelial cell line. Am J Physiol Lung Cell Mol Physiol 291: L407-L416.
25. Sturges NC, Wikström ME, Winfield KR, Gard SE, Brennan S, et al. (2010) Monocytes from children with clinically stable cystic fibrosis show enhanced expression of Toll-like receptor 4. Pediatr Pulm 45: 883-889.
26. Augarten A, Paret G, Avneri I, Akons H, Aviram M, et al. (2004) Systemic inflammatory mediators and cystic fibrosis genotype. Clin Exp Med 4: 99-102.
27. Schmitt-Grohé S, Naujoks C, Bargon J, Wagner TO, Schubert R, et al. (2005) Interleukin-8 in whole blood and clinical status in cystic fibrosis. Cytokine 29: 18-23.
28. Kronborg G, Hansen MB, Svenson M, Fomsgaard A, Hoiby N, et al. (1993) Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. Pediatr Pulmonol 15: 292-297.
29. Elborn JS, Nixon L, Bell SC, Shale DJ, (1994) On tumor necrosis factor α in CF. Pediatr Pulmonol 17: 411-412.
30. Sagel SD, Accurso FJ, (2002) Monitoring inflammation in CF. Clin Rev Allerg Immunol 23: 41-57.
31. Langezaal I, Coecke S, Hartung T, (2001) Whole blood cytokine response as a measure of immunotoxicity. Toxicol In Vitro 15: 313-318.
32. Nixon LS, Yung B, Bell SC, Elborn JS, Shale DJ, (1998) Circulating immunoreactive interleukin-6 in cystic fibrosis. Am J Respir Crit Care Med 157: 1764-1769.
33. LaRosa JC, He J, Vupputuri S, (1999) Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA 282: 2340-2346.
34. Falagas ME, Makris GC, Matthaiou DK, Rafailidis PI, (2008) Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 61: 774-785.
35. Takano K, Yamamoto S, Tomita K, Takashina M, Yokoo H, et al. (2010) Successful treatment of acute lung injury with pitavastatin in septic mice: potential role of glucocorticoid receptor expression in alveolar macrophages. J Pharmacol Exp Ther 336: 381-390.
36. De Bont N, Netea MG, Rovers C, Smilde T, Demacker PN, et al. (1998) LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors. Atherosclerosis 139: 147-152.
37. Goldman F, Hohl RJ, Crabtree J, Lewis-Tibesar K, Koretzky G, (1996) Lovastatin inhibits T-cell antigen receptor signaling independent of its effects on ras. Blood 88: 4611-4619.
38. Niwa S, Totsuka T, Hayashi S, (1996) Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 18: 669-675.
39. Terkeltaub R, Solan J, Barry M, Santoro D, Bokoch GM, (1994) Role of the mevalonate pathway of isoprenoid synthesis in IL-8 generation by activated monocytic cells. J Leukocyte Biol 55: 749-755.
40. Horn MP, Knecht SM, Rushing FL, Birdsong J, Siddall CP, et al. (2008) Simvastatin inhibits Staphylococcus aureus host cell invasion through modulation of isoprenoid intermediates. J Pharmacol Exp Ther 326: 135-143.
41. Chello M, Anselmi A, Spadaccio C, Patti G, Goffredo C, et al. (2007) Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery. Ann Thorac Surg 83: 1374-1380.
42. Fessler MB, Young SK, Jeyaseelan S, Lieber JG, Arndt PG, et al. (2005) A role for hydroxy-methylglutaryl coenzyme A reductase in pulmonary inflammation and host defense. Am J Respir Crit Care Med 171: 606-615.
43. Ou XM, Wang BD, Wen FQ, Feng YL, Huang XY, et al. (2008) Simvastatin attenuates lipopolysaccharide-induced airway mucus hypersecretion in rats. Chin Med J 121: 1680-1687.
44. Sakoda K, Yamamoto M, Negishi Y, Liao JK, Node K, et al. (2006) Simvastatin decreases IL-6 and IL-8 production in epithelial cells. J Dent Res 85: 520-523.
45. Johnson BA, Iacono AT, Zeevi A, McCurry KR, Duncan SR, (2003) Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 167: 1271-1278.
46. Kiener PA, Davis PM, Murray JL, Youssef S, Rankin BM, et al. (2001) Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int Immunopharmacol 1: 105-118.
47. Corsini A, Mazzotti M, Raiteri M, Soma MR, Gabbiani G, et al. (1993) Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG CoA reductase. Atherosclerosis 101: 117-125.
48. Shyamsundar M, McKeown ST, O'Kane CM, Craig TR, Brown V, et al. (2009) Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 179: 1107-1114.
49. Földes G, von Haehling S, Okonko DO, Jankowska EA, Poole-Wilson PA, et al. (2008) Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure. Int J Cardiol 124: 80-85.
50. Zhao D, Pothoulakis C, (2003) Rho GTPases as therapeutic targets for the treatment of inflammatory diseases. Expert Opin Ther Targets 7: 583-592.
51. Kreiselmeier NE, Kraynack NC, Corey DA, Kelley TJ, (2003) Statin-mediated correction of STAT1 signaling and inducible nitric oxide synthase expression in cystic fibrosis epithelial cells. AJP- Lung Physiol 285: L1286-L1295.
52. Rowntree RK, Harris A, (2003) The phenotypic consequences of CFTR mutations. Ann Hum Genet 67: 471-485.
53. O'Sullivan BP, Freedman SD, (2009) Cystic fibrosis. Lancet 373: 1891-1904.